Lead Product(s) : Idelalisib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Forbion
Deal Size : $81.1 million
Deal Type : Series A Financing
Two biotechs Merge to Form Calluna, with €75M in Hand to Focus on Immunotherapy Antibodies
Details : Calluna Pharma focuses on the clinical stage lead program CAL101, which is a monoclonal antibody that neutralizes the bioactivity of S100A4 & implements DAMP protein for idiopathic pulmonary fibrosis.
Brand Name : CAL101
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 22, 2024
Lead Product(s) : Idelalisib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Forbion
Deal Size : $81.1 million
Deal Type : Series A Financing
Lead Product(s) : Idelalisib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia
Details : Zydelig® (idelalisib) is approved in the U.S. for the treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities.
Brand Name : Zydelig
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 14, 2022
Lead Product(s) : Idelalisib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
